Market

Ventyx Biosciences sets terms for IPO valuing autoimmune-drug firm at up to $823M



Ventyx Biosciences sets terms for IPO valuing autoimmune-drug firm at up to $823M



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.